TB-PRACTECAL, a clinical trial led by Médecins Sans Frontières (MSF), has found that a new, all-oral, six-month treatment regimen is safer and more effective at treating rifampicin-resistant tuberculosis (RR-TB) than the current accepted standard of care. These results signal the start of a new chapter for people with drug-resistant (DR)-TB, who currently face lengthy treatment regimens. Read Here.
“Why am I passionate about TB? It’s the deadliest disease in human history, but for most of human history we couldn’t do much about it. However, since the mid-1950s, TB has been curable — yet we still
"Danaher and Cepheid are using a printer-ink business model to overcharge for tuberculosis tests, thus resulting in millions of people going undiagnosed every year, many of whom will die." Watch the f
The World Health Organization’s (WHO’s) 2023 Model Lists of Essential Medicines, published in July 2023, features key updates to the tuberculosis (TB) section. These complement current WHO recommendat